Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
12 11 2022
12 11 2022
Historique:
received:
08
08
2022
accepted:
28
10
2022
entrez:
13
11
2022
pubmed:
14
11
2022
medline:
16
11
2022
Statut:
epublish
Résumé
Coronavirus infections are a world-wide threat to human health. A promising strategy to develop a broadly active antiviral is the use of fusion proteins consisting of an antibody IgG Fc region and a human ACE2 domain to which the viral spike proteins bind. Here we create antiviral fusion proteins based on IgM scaffolds. The hexameric ACE2-IgM-Fc fusions can be efficiently produced in mammalian cells and they neutralize the infectious virus with picomolar affinity thus surpassing monomeric ACE2-IgM-Fc by up to 96-fold in potency. In addition, the ACE2-IgM fusion shows increased neutralization efficiency for the highly infectious SARS-CoV-2 omicron variant in comparison to prototypic SARS-CoV-2. Taken together, these multimeric IgM fusions proteins are a powerful weapon to fight coronavirus infections.
Identifiants
pubmed: 36371561
doi: 10.1038/s42003-022-04193-z
pii: 10.1038/s42003-022-04193-z
pmc: PMC9653429
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Spike Glycoprotein, Coronavirus
0
Antiviral Agents
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
Immunoglobulin M
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1237Informations de copyright
© 2022. The Author(s).
Références
Immunity. 2021 Jul 13;54(7):1611-1621.e5
pubmed: 34166623
Sci Rep. 2021 May 19;11(1):10617
pubmed: 34012108
Virology. 2021 May;557:70-85
pubmed: 33676349
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Lancet Respir Med. 2020 Nov;8(11):1154-1158
pubmed: 33131609
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Cell Host Microbe. 2021 Mar 10;29(3):322-324
pubmed: 33705702
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949
pubmed: 28096333
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28046-28055
pubmed: 33093202
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8575-E8584
pubmed: 28973899
Nat Struct Mol Biol. 2021 Feb;28(2):202-209
pubmed: 33432247
J Virol. 2020 Oct 27;94(22):
pubmed: 32847856
EMBO Mol Med. 2012 Oct;4(10):1015-28
pubmed: 22837174
Nature. 2021 Jul;595(7869):718-723
pubmed: 34082438
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10183-8
pubmed: 23733956
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
J Vis Exp. 2014 Nov 04;(93):e52065
pubmed: 25407402
Antibodies (Basel). 2020 Oct 13;9(4):
pubmed: 33066119
Antiviral Res. 2021 Dec;196:105197
pubmed: 34774603
Science. 2021 Apr 2;372(6537):
pubmed: 33795432
Nano Today. 2022 Oct;46:101580
pubmed: 35942040
Clin Cancer Res. 2007 May 1;13(9):2745-50
pubmed: 17473208
Nat Commun. 2020 Apr 24;11(1):2070
pubmed: 32332765
Sci Adv. 2022 Jul 15;8(28):eabn4188
pubmed: 35857504